ArticleScientific reports2026
Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed a CancerMaster-targeted next generation sequencing (NGS) panel covering 524 key genes specifically designed for the multidimensional molecular profiling of solid tumors. We aimed to establish CancerMaster as an asynchronous and parallel one-stop automated analysis pipeline with a reporting system to overcome the delay in existing NGS approaches. This panel can detect common genomic alteration types, including single nucleotide variants/indels and copy number variants (CNVs), fusions, Epstein-Barr virus/human papillomavirus infection, microsatellite instability (MSI), tumor mutational burden (TMB) status, and human leukocyte antigen typing. Using reference materials, CancerMaster demonstrated 100% reproducibility, 99% analytical sensitivity, and high accuracy (94%). Analytical performance for other biomarker classes-including CNVs, fusions, MSI, TMB, and viral detection-was evaluated separately. In a cohort of 668 patients, we identified actionable mutations, including in TP53, KRAS, and PIK3CA, and CNVs, e.g., ERBB2 amplification in gastric (n = 412) and colorectal (n = 66) cancers. MSI and TMB were strongly correlated in all patients (n = 668, r = 0.75; p < 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.